Life Sciences Archive » March, 2018

Life Sciences - March, 2018

366 articles

• Kimberly-Clark Won't Face Suit Over Ebola Prevention Gowns
• Co. Punished For Dodging Discovery Tied To $75M IP Loss
• Pharmacy Owner Gets 13 Years For $4.3M Kickback Plot
• Reckitt Doesn't Own Airborne's Box Design: Supplement Co.
• Ex-Katten Atty Should Hand Over A Half-Million, Feds Say
• Gov't Can't Expand FCA Case Over Hep B Tests, Judge Says
• Goodwin Liu Talks Academia, Constitutional Law, Oxtail Stew
• Costco Asks 9th Circ. To Bury Supplement False Ad Suit
• Bard Owes Injured Woman $3.6M In IVC Bellwether, Jury Finds
• Ex-Fed. Circ. Chief On Court's Fading Power, 101 Woes
• Why Bristol-Myers Applies To Federal Class Actions
• BigLaw Doesn't Have A Diversity Problem
• First Bard Vein Filter Bellwether Heads To Jury
• Parents Can Sue Sorin Over Heart-Valve Death, Judge Says
• WashU, WARF Offer Closing Arguments In Patent Royalty Trial
• Mylan Must Face Many Of Investors' EpiPen Fraud Claims
• Trial Court Disrespected China, Exporters Tell Justices
• Cozen O'Connor Adds LeClairRyan IP Attorney In D.C.
• 9th Circ. Revives $3M In Damages Against IKOR, Execs
• Shook Hardy Adds Life Sciences, Food & Bev Pro In Philly
• Roman J. Israel, Esquire, Meet Donald J. Trump, POTUS
• Impax Ends Acne Drug Pay-For-Delay Suit For $20M
• Theranos Indirect Investors Seek Cert. In Securities Suit
• Bard Exec Defends Handling Of Complaints At Vein Filter Trial
• Whistleblower Atty Says Shield 'Came Up With' FCA Scheme
• Pharmacies Again Sue Express Scripts After Talks Fail
• Bayer Unit Wins $17.6M Over Herbicide Supplier Price Hikes
• Biotech Co. In Contempt For Public Statements On IP Row
• Deals Rumor Mill: GSK, Platinum Equity, Gazprom
• Teva Skirts $235M Infringement Verdict In Coreg Patent Row
• Johnson & Johnson Can't Escape Benecol Labeling Suit
• Judge OKs Drug Distributor Info Sharing In Opioid MDL
• Fed. Circ. Pauses PTAB Review Of Restasis Patents
• Chinese Streaming Co. Leads 4 IPOs Netting $828M
• Essure Users Must Combine 13K Injury Suits, Judge Says
• Biz Misled On Gene Therapy Toxicity Pre-IPO, Investors Say
• Biogen Lacked Intent To Defraud, Shareholder Suit Judge Says
• Pharmacy Owner Gets 5 Years For $10.5M Tricare Fraud
• Timing Of Patent-Eligibility Challenges In Pharma Cases
• We Need A Cybersecurity Framework For Law Firms
• How NY And NJ Medical Cannabis Regulations Are Evolving
• US Chips Away At S. Korean Car, Drug Barriers
• Cherokee Say Opioid Claims Don't Belong In Federal Court
• ​​​​​​​Anxiety Patients, Others Now Qualify For NJ Medical Pot
• Equity Partnership Isn't What It Used To Be
• GSK Buys Out Novartis Stake In Healthcare JV For $13B
• Ex-Workers Press For Sanctions In Colgate ERISA Suit
• Examining Exergen For Patent Eligibility Clues
• GSK Has One Week To Hand Over Zofran Data, Judge Says
• Clinics May Eye Quick Deals In Lost Embryo Cases
• Shkreli To Appeal Fraud Conviction, 7-Year Prison Sentence
• Investors Battle Intuitive On Bid For Win In Stock-Drop Suit
• SEC Settles With Drugmaker Akorn Over Revenue Reports
• Medical Device Co. Must Face Claims In Hip Implant MDL
• WashU Kicks Off Trial Over Drug Patent Licensing Royalties
• CytRx Scoffs At $685K Fees Request In Shareholder Suit
• Diagnostic Lab Escapes Suit Over Cancer Misdiagnosis
• Generic Cos. Tell Fed. Circ. Not To Halt PTAB Restasis IPRs
• 6 Companies Fill IPO Pipeline With Filings Totaling $656M
• Colgate Says No Sanctions Warranted In ERISA Suit
• Doc Charged In Insys Case Gets Limited Prescription Power
• PacBio DNA Patent Survives Eligibility Challenge, Judge Finds
• Regeneron Must Pay Attys' Fees After 'Severe Misconduct'
• Boehringer Wins 1st Bellwether In Conn. Pradaxa Risk Suit
• Biogen Wants Jury Verdict Overruled In MS Drug Patent Row
• Is The US Patent System In Trouble? Part 2
• Consumers Push For Cert. In Contaminated Ranbaxy Pills Suit
• Pharma Co. Escapes NY Derivative Suit Over Director Pay
• AbbVie Ordered To Pay $3M In AndroGel Retrial
• Higher Ed Should Approach Marijuana Laws Cautiously
• NuVasive Investors Settle Kickback Class Action For $7.9M
• Judging A Book: Hardiman Reviews 'Without Precedent'
• CVS, Walgreens, Rite Aid Settle Impax Pay-For-Delay Suit
• Vitamin C Case Brings A First For China, US Supreme Court
• Ensnarement Defense Violates Jury Trial Right, Justices Told
• Drugmaker's Investors Sue For Books On $885M In Sanctions
• New FDA Policy Takes Aim At Big Compounders
• Is The US Patent System In Trouble? Part 1
• Pa. Court Won't Rethink Axing Bar On Risperdal Punitives
• Bayh-Dole Could Be A Drug Pricing Fix, If The Feds Want It
• Trump Says Fed. Gov't Will Sue Drugmakers Over Opioids
• Doc Lands 8 Years, Owes $9M For Shady Medicare Billing
• 6 Firms To Lead 8 IPOs Exceeding $3.5B As Deals Heat Up
• Alvogen Beats Infringement Suit Over Suboxone Generic
• 2nd Circ. Affirms Dismissal Of Organic Baby Food Claims
• Alere, Feds Reach $33.2M Deal In Medical Device FCA Suit
• Cherokee Push Judge To Send Opioid Suit To State Court
• Top Tax Changes For Law Firms: What Lawyers Need To Know
• Roundup Warning Label Ruling Less Surprising Than It Seems
• Alice Angst Intensifies
• Creditor Loses Bid For Nearly $4M Of BioChemics-SEC Deal
• 4 Highlights From Congress' Two-Day Opioid Hearing
• AbbVie Must Be Sent Message, Jury Told In AndroGel Trial
• Shire Wins Adderall Suit While Loser Gets Sanction Request
• Law360's Life Sciences Editorial Advisory Board
• 5th Circ. Rejects IRS Bid To Pause Anti-Inversion Appeal
• FTC's Big ViroPharma Loss Has Antitrust Silver Lining
• Gibson Dunn DQ Sought By Ex-Pharma Execs In RICO Suit
• 6 Consumer Protection Enforcement Trends To Watch At FTC
• Shkreli Cuts $1.5M Deal To End KaloBios Investors' Suit
• Discovery Challenges In Transnational Class Actions
• Companies Should Avoid The BigLaw Bonus Structure
• House Passes 'Right To Try' Experimental Treatments Bill
• Fed. Circ. Says Drug Co. Briefs Too Long In Suboxone Appeal
• Israeli Pharma Co., CEO Can't Escape Stock-Drop Suit
• PTAB Deems 2 Rulings Nixing AIA Reviews 'Informative'
• Vitamin World Creditor Seeks To Convert Ch. 11 To Ch. 7
• Ark. Sues Drugmakers, Distributors Over Opioid Epidemic
• Gov't Slams Ex-Katten Atty's Move To Nix Conviction
• Ill. Man Says Insys Rep's Lies Got Him Hooked On Opioids
• Puma Biotech Insider Trader Pays Penalty, Can Go Home
• Fed. Circ. Says No Fees For PTAB Indefiniteness Finding
• Meningitis Pharmacist's Direct Victims Were Providers: Judge
• Atty's Widow Says Mass. Court Buoys Her $3M GSK Verdict
• A Potentially Promising Future For Pa. Medical Marijuana
• Calif. Medical Supplier Fights DOJ's Entry Into FCA Suit
• IRS Asks 1st Circ. To Uphold Order To Return Excess Subsidy
• Sessions Memo Backs Death Penalty In Opioid Cases
• Endo, Others Ink $166M Lidoderm Pay-For-Delay Settlements
• Globus Recruits Violating Noncompete Deals, DePuy Says
• Chief Innovation Officer — The New Star On Legal Teams
• Reps. Introduce Wide-Ranging Bill To Bolster Patent Owners
• More Sharing Of Opioid Sales Data Possible, DEA Chief Says
• FTC Loses Assault On Shire Unit's Serial FDA Petitions
• Firms Clamor To Lead Cancer Drug Stock-Drop Suit In Boston
• Medicaid Rule Can't Govern Radioactive Drugs, Suit Says
• Blue Cross Unit Fights Sanctions Bid In Aggrenox MDL
• Allergan Drug Buyers Urge 1st Circ. To Keep Class Cert.
• Relator Assails Early Out For Janssen, J&J In Off-Label Row
• FDA Warning Wire: Birds And Bugs Plague Drug Plant
• Walgreens Strikes $5.5M Drug Overcharge Deal With Mass. AG
• Momenta, Sandoz Can't Dodge Amphastar Antitrust Suit
• EXCLUSIVE: Behind The Downfall Of Latham's Chairman
• It's Time For The US To Re-Engage With The TPP
• Acetris Questions Made-In-US Standard For Drugs
• Eligibility Rulings May Lead To Shift In Patent Prosecution
• National Lawyers Need National Licensing For National Courts
• How Regulatory Power Is Moving To The States
• Mass. Court Ruling Eases Way For Brand Drug Label Claims
• Valeant, Pershing Get Initial OK On $290M Investor Deals
• AstraZeneca Owes $192M For Cancer Drug Rights, Rival Says
• Co. Did Not Warn Of Mesh Product Risks, NJ Jury Told
• 'China's Netflix' Leads 6 IPO Launches Exceeding $3B Total
• Experts Didn't Prove Hernia Mesh Caused Injuries, Court Says
• Rite Aid Defends Rx Discount Program In Co-Pay Cost Row
• Oglala Sioux Tribe Targets Drug Cos. With Opioid Suit
• Treasury Urges 5th Circ. To Reinstate Anti-Inversion Rule
• Clyde & Co. Nabs Ex-Curtis Int'l Arbitration Pro In Paris
• Trump Unveils 4-Point Plan For Easing Opioid Crisis
• Illumina Says Sales Ban Needed To Stop Ariosa Infringement
• Tribe Asks Fed. Circ. To Pause Restasis Patent Reviews
• High Court Won't Hear Two Consumer Protection Suits
• Doc Can Opine In Diet Pill Death Suit, NJ Appeals Court Says
• Acne Med Pay-For-Delay Deal Sped Up Generic, Exec Says
• High Court Won't Review FCA First-To-File Case
• Teva Can't Get Justices To Nix Suit Alleging Drug-Cancer Link
• Western Pa. Cities Latest To Strike At Opioid Manufacturers
• Justices Refuse To Hear Pot Co.'s Challenge Of IRS Probe
• Opioid Solutions: Insurance, Legislation Or Litigation?
• NJ Employers Should Note Evolving Cannabis Laws
• When 'A' Stands For Preemption
• Private Equity FCA Suit More Likely Outlier Than Omen
• SEC's Silicon Valley Scrutiny Comes To Bloom In New Cases
• Philly Litigator Rips Opioid Defense Attys At Conference
• 'Unicorn' Zscaler Surges After Pricing Upsized $192M IPO
• Pharma Cos. Liable For Generic Labels, Mass. Top Court Says
• Optical Co. Says Ex-Biz Partner's IP Suit Too Late
• Summary Judgment Denial Clears Path For Abilify Trials
• Hospital Seeks Data On Worker Fired After Skipping Flu Shot
• Drug Cos. Say Cherokee Opioid Suit Must Stay In Fed. Court
• Hernia Mesh Maker Can't Force Chubb Unit To Cover IP Suit
• NY Docs Got Lap Dances, Booze From Insys, DOJ Says
• Aegerion Placed Under Supervision In Misbranding Settlement
• Feds Should Own Gilead Hep C Patent, Nonprofit Says
• Robins Kaplan Adds Ex-Kasowitz Benson IP Pro In Calif.
• Fed. Circ. Affirms Exergen Ruling Doesn't Set Precedent
• 4 Firms To Steer IPOs Totaling $850M Led By Dropbox
• Stock-Drop Suit Targeting HeartWare Survives Dismissal Bid
• A Chat With Littler Info Chief Durgesh Sharma
• PE Firm Platinum Offers $2.1B For J&J Glucose Testing Unit
• Changes To Rule 23 Are Coming, Are You Prepared?
• 9th Circ. Urged To Rethink HIPAA Probe Coverage Ruling
• 9th Circ. Revives Whistleblower's FCA Row Against Merck
• Bankrupt Laser Co. Hid Assets To Duck Court Judgments: Suit
• Dem Bill Takes On Tribal Opioid Crisis With New Program
• Menominee Latest Tribe To Sue Pharma Cos. Over Opioids
• Cigna, Express Scripts To Face Tough Antitrust Review
• GSK Says FDA Barred Warning Of Suicide Risks With Paxil
• Deals Rumor Mill: Alibaba, Bayer, BP
• Consultant Co. Wants Out Of $1.76M Suit Over Alleged Scam
• Drugmakers Get Blowback As 340B Changes Gain Steam
• Abbott Says Ex-Employee Should Pay For Dismissed FCA Suit
• Investors Can't Peg ProNAi For Failed Cancer Drug
• Calif. Duty To Defend Is In Jeopardy
• Personal Jurisdiction In 3rd Circ. After 'Shuker'
• Collaborative Workspace Co. Scores $58M In Global Push
• VC Firm Flagship Commits $50M To Gene Control Researcher
• False Claims Act An Unlikely Tool In Opioid Crackdown
• Fed. Circ. Backs PTAB In Upholding Uterine Endoscope IP
• Tax Court Flubbed Analysis In Medtronic Case, 8th Circ. Told
• Tribes Need Gov't Funding To Fight Opioids, Senate Panel Told
• New AHIP Chief Dishes On Health Policy Vision
• GSK Says It Can't Find Marketing Contracts In Zofran MDL
• Deals Rumor Mill: Siemens, Deutsche Bank, Ardian
• Second Fertility Clinic Sued Over Destroyed Eggs
• Theranos CEO Holmes Settles Over $700M Fraud, SEC Says
• Idexx Underpaid Lyme Disease Patent Royalties, UT Says
• What To Expect From DOJ Shift In Marijuana Enforcement
• Trends In China's Food And Packaging Laws: Part 1
• Orexigen Gets Interim OK For $7.5M DIP To Fund Sale Process
• Shkreli's Sentence Shows Risks Of Open Defiance
• Ex-NFLer, Atty Fight SEC's Stock Scam Wins At 9th Circ.
• Illumina Tells Fed. Circ. Ariosa Doesn't Deserve 2nd Chance
• Judge Schedules First 3 Trials In Abilify MDL
• House Fails To Pass 'Right-To-Try' Bill After Dems Object
• 7th Circ. Affirms Fired Atty's Fee After Second Review
• Tikehau Nabs $50M For Health-Focused VC Fund
• Opioid Bills Would Up Feds' Control Over Quotas, Imports
• Generic Drug Co. Can Continue Arbitration Against Ranbaxy
• FDA Warning Wire: Online Eye Exam Gets Agency Side-Eye
• Oregon Enacts Drug Price Transparency Law
• Tribe Says Opioid Makers Caused 'Public Health Crisis'
• Lawyering A La Carte: Unbundled Dispute Resolution Services
• Cigna Must Face RICO Claims In Insured Price Suit
• FCA Materiality May Return To High Court
• Syngenta Agrees To Pay $1.5B To End Corn GMO Class Claims
• Ohio Pension OK'd To Lead Investors Against Mallinckrodt
• Recent Patent-Eligibility Cases Leave Unanswered Questions
• $40M Acne Med Pay-For-Delay Trial Kicks Off In Boston
• PTAB Denies Coherus' Challenge To 2 Enbrel Patents
• Pharmacist, Employee Get Prison For $30M Tricare Fraud
• EU Says Pay-For-Delay Drug Settlements Still Down
• Drugmaker Orexigen Opens Del. Ch. 11 With $226M In Debt
• Discovery Fraud Kills Suppliers' Privilege In Test Strips Row
• You're Perfect, Now Change: Perfectionism Hurts Lawyers
• Medical Device Co. Says Atty's Consultant Scam Cost It $1.8M
• Cook Medical's Vein Filter Suit Tossed As Time-Barred
• 11th Circ. Creates Headaches For Judges, Defense Attorneys
• Clorox Swallows Vitamin Maker In $700M Deal
• Grassley, Feinstein Debate Judicial Vetting, Obstruction
• Why The 'Blue Slip' Battles Are Becoming White Hot
• Senior Judges Fill The Void Left By Rampant Vacancies
• Walgreens Must Face Bulk Of Suit Over Rx Club Prices
• How Far Right Can The President Pull The Courts?
• Impax Heads To Rare Trial In Pay-For-Delay Case
• Tribe Says PTAB Can't Weigh Restasis Patents During Appeal
• Dr. Reddy's Escapes FCA Suit Over Drug Packaging
• FDA Accuses Scope Makers Of Flouting Safety Studies
• Health Hires: Aronberg, Bracewell, Miles, Polsinelli, Sidley
• Abbott Unit Covered By Patent Safe Harbor, Magistrate Says
• Firm's Suit Over Fees In Novartis Row Paused Over Atty Exit
• Texas Pharma Delivery Co. Wins $24M In Tech Battle
• GlaxoSmithKline 'Pay For Delay' Suit Heads To EU Court
• Johnson & Johnson Hit With $35M Verdict In Pelvic Mesh Trial
• Ex-Biotech CEO Blasts SEC's 'Guilt By Association' Suit
• FTC Materials Barred In Imminent Solodyn Pay-For-Delay Trial
• The New USPTO Examiner Manual And 102(e) Prior Art
• Shkreli Gets 7 Years In Prison For Securities Fraud
• 3rd Circ. Gets It Partly Right On Component Preemption
• Genentech Fights For $5.8M In 'Exceptional' IP Attys Fees
• Soon-Shiong Firm Fights $47M Post-Merger Cash Tap Suit
• 11th Circ. Upholds Yale Doc's Fee Award In Defamation Suit
• Cancer-Focused Biotech Co. Prices $60M IPO At Low End
• 7th Circ. Won't Revive Knee Implant MDL Bellwether
• Baker McKenzie Snags 5 Ex-Hogan Attys, Opens LA Office
• DOJ Leaning More On FCA In Fight Against Opioid Abuse
• Calif. Claims Cancer Nonprofit Inflated Value By Millions
• PTAB Hands Out Mixed Results In Sleep-Aid Challenges
• Fed. Circ. Says Exergen Thermometer Patents Survive Mayo
• USPTO Defends Charging Attys' Fees At Full Fed. Circ.
• Parkinson's-Fighting Biotech Snags $75M In Series A Funding
• Heart Pump Maker Pays $3.1M To Settle Kickback Charges
• Littler Adds Ex-Alexion Pharma Counsel As Shareholder
• Pot Business Asks 10th Circ. For Equal Treatment From IRS
• 5 Sens. Introduce Bill To Bar Tribal Immunity Deals At PTAB
• Don't Revive Restasis Patents, Generic Cos. Urge Fed. Circ.
• BioCryst Shareholders Sue Over Idera Merger Plan
• Bone Broth Nutrition Biz Reaps $103M In Funding
• Goldberg Segalla Boosts NY IP Group With Ex-Polsinelli Atty
• Will High Court Provide Clarity On 'Clear Evidence'?
• Roche Released From Suit Over Man's Bowel Disease
• Pay Our Attorneys' Fees, USPTO Says, Even When We Lose
• Pharma Co. Tells CIT Its Drugs Are Made In U.S., Not India
• Shkreli Attys Call 15-Year Sentence 'Severe,' Ask For 1.5
• McKesson Says It Acted On Compliance Concerns In 2008
• Retrial Begins In Original Testosterone MDL Bellwether
• EPO Again Reports Record High In Patents Granted
• Opioid MDL To Get Litigation Track Amid Settlement Talks
• Blue Cross, Takeda Settle Actos Cancer Claims
• Calif. Court Restores Patient's $4.5M Win In Hip Defect Suit
• Insurer Needn't Cover $5M HIPAA Probe Costs, 9th Circ. Says
• Bayer, J&J Look To Bar Amended Master Xarelto Complaint
• What Happens If The DOJ Joins The Opioid MDL?
• Valeant Looks To Shake Investment Fund's State RICO Claims
• Amgen Says FDA Flouted Own Rules In Calcium Drug Row
• Cosmetics Companies Using Instagram Face Regulatory Risk
• Deputy AG Asks For Insurers' Help To End Opioid Crisis
• DOJ Civil Division Pick Promises A False Claims Focus
• Dietary Supplements And FDA: Potential For Partnership?
• Cannabis' CEQA Challenge
• Legal Group Urges 1st Circ. To Flip Asacol Class Cert.
• 3rd Circ. Gives 'Hybrid' Med Devices New Liability Shield
• Wilson Sonsini Snags DOJ, FTC Vet From Gibson Dunn
• FDA Backs 23andMe Tests For Breast Cancer Risks
• Teva Blocking Senate Opioid Investigation, McCaskill Says
• Gov't Urges Justices To Flip Vitamin C Price-Fixing Decision
• Feds Seek 15-Year Term For Martin Shkreli
• FDA Warning Wire: Bevy Of Big-Name Cos. Targeted
• Barnes & Thornburg Opens Office With Ex-Cooley Partner
• Express Scripts Escapes Processing-Fee Suit
• Tribes Hit Pharma Cos. With Suit Over Opioid Crisis
• Where White Collar Enforcement Is Heading
• Searching For 'Act Of Infringement' Under Hatch-Waxman
• 10 Tips For Working With IT To Preserve Data
• Chinese Vaccine Co. Sues 'Dissident' Shareholders Over Coup
• Riker Danzig, Cole Schotz Launch NJ Cannabis Practices
• J&J Unit Can't Shake $15M Pelvic Mesh Verdict In NJ
• Whistleblowers Assail Gilead's Escobar Defense At High Court
• 2 Firms Edge Ahead In February Aided By Blank Check IPOs
• Fujifilm Sues Hologic For Mammography Patent Infringement
• PTAB Upholds Claims Of 2 Glucose Monitoring Patents
• DEA Agrees To Large Data Release In Opioid MDL
• Kilpatrick Townsend Hires Ex-Holland & Knight IP Partner
• Tech 'Unicorn' Leads 3 Cos. To Launch IPOs Totaling $286M
• Bill Would Boost Tribes' Access To Opioid Treatment Funds
• Justices Spurn Endo, NH Row Over Counsel In Opioid Probe
• Shkreli Must Give Up $7.3M, Wu-Tang Clan Album
• How To Guide Your Client's New Drug Past An FDA Quick Kill
• Profs Tell High Court 2nd Circ. Wrong On Chinese Exporters
• J&J Asks 3rd Circ. To End Suit Over Talc-Based Baby Powder
• Exploring Limits Of Anti-Kickback Law Employee Safe Harbor
• Class Action Lawyers Behaving Badly
• Mylan Can't Escape Celgene's Suit Over Skin Cancer Patent
• Juno Investor Seeks Records To Look Into $9B Celgene Deal
• NJ Firefighter Cops To Role In $50M Drug Fraud Scheme
• Cherokee Nation, Drug Cos. Wrangle Over Opioid Suits
• FCA Decision Tracker: Continued Interpretations Of Escobar
• Health Care Cos. Lose Class Bid In Janssen Junk Fax Suit
• Fed. Court Won't Hear Shumaker Loop IP Malpractice Suit
• Insurers Defend $67M Antitrust Win Amid Mylan Appeal
• FasciaBlaster Inventor Sanctioned In Failed Defamation Suit
• Lawyers Needed To Cut Through The Weeds Of Pot M&A
• Brand Battles: 'Lord Of The Rings,' Bayer, MLB, Scotch Whisky
• Deals Rumor Mill: SlimFast, United Grinding, IGM Resins
• Par Pharma Blocks Blood Pressure Drug Rival
• Tricida Secures $100M In Debt Financing For Latest Drug
• Impermissibly Redefining 'Long-Felt Need' Using Hindsight
• Jurisdiction Issues Dog Multistate Class Actions
• 'Revolving Door' At DEA Faces Scrutiny In Opioid MDL
• 3rd Circ. Nixes Part Of 'Hybrid' Medical Device Suit
• Trump May 'Do Some Litigation' Against Opioid Cos.
• Wrist Wear Co. Hits Ch. 11 With Plans To Sell IP, Sue Apple
• Valeant To Shell Out $58M To End Solodyn Pay-For-Delay MDL
• Ex-Hunton Atty Urges 2nd Circ. To Undo Insider Trading Rap
• Jury Says Omnicare Didn't Misclassify Drivers In FLSA Suit
• Details Emerge On DEA Data Release In Opioid MDL
• Allergan, Tribe Rush To Appeal PTAB Decision To Review IP
• Justices Urged To Reverse 'Indefensible' On-Sale Bar Ruling
• Belgian, French Cartel Watchdogs Raid Cosmetics Companies
• PTAB Upholds Eye Treatment Tool Patent
• Make An Informed Choice About Arbitration
• FTC, NY Assail Toss Of Memory Booster Suit At 2nd Circ.
• Miami-Dade County Hires Legal Team To Launch Opioid Suit
• Barnes & Thornburg Adds IP, Corporate Attys In Chicago
• Mintz Levin Adds Morgan Lewis Tech Duo In Boston
• Protecting Privilege In Litigation Financing Negotiations